GlobeNewswire·Nov 11, 2026, 8:44 AM ET

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

Akari Therapeutics announced participation in a Virtual Investor "What This Means" segment featuring newly appointed Chief Business Officer Vatnak Vat-Ho.
Vat-Ho discussed his oncology business development background, strategic partnering experience, & reasons for joining Akari.
The discussion highlighted the potential of Akari's novel PH1 payload platform, its differentiated dual mechanism of action, & opportunities across multiple ADC constructs.
Vat-Ho outlined priorities as Chief Business Officer, including advancing strategic collaborations, supporting investor engagement, & translating scientific progress into long-term value.
Akari's lead candidate AKTX-101 targets the Trop2 receptor with the proprietary PH1 spliceosome-modulating payload, which induces cancer cell death & activates immune systems.
Preclinical data shows AKTX-101 has significant activity, prolonged survival, & potential synergy with checkpoint inhibitors compared to ADCs using traditional payloads.
The Company initiated IND enabling studies for AKTX-101 with a goal to start First-In-Human trials by mid-2027.
Akari is also developing AKTX-102, an ADC candidate targeting the CEACAM5 antigen using the PH1 payload & a novel antibody construct.